Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

Nature

Volumn 512, Issue 1, 2014, Pages 74-77

  Whitney, James B ^a,b   Hill, Alison L ^c   Sanisetty, Srisowmya ^a   Penaloza Macmaster, Pablo ^a   Liu, Jinyan ^a   Shetty, Mayuri ^a   Parenteau, Lily ^a   Cabral, Crystal ^a   Shields, Jennifer ^a   Blackmore, Stephen ^a   Smith, Jeffrey Y ^a   Brinkman, Amanda L ^a   Peter, Lauren E ^a   Mathew, Sheeba I ^a   Smith, Kaitlin M ^a   Borducchi, Erica N ^a   Rosenbloom, Daniel I S ^c   Lewis, Mark G ^d   Hattersley, Jillian ^e   Li, Bei ^e   Hesselgesser, Joseph ^e   Geleziunas, Romas ^e   Robb, Merlin L ^f   Kim, Jerome H ^f   Michael, Nelson L ^f   Barouch, Dan H ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d BIOQUAL INC   (United States)

^e GILEAD SCIENCES   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTI-RETROVIRAL AGENTS; CARRIER STATE; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; KINETICS; MACACA MULATTA; MALE; PROVIRUSES; RECTUM; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; TREATMENT FAILURE; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84905565097     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13594     Document Type: Article

References (29)

1. 1 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
2. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340, 1605-1613 (1999).
3. Chun, T. W., Davey, R. T., Jr, Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of HIV after stopping therapy. Nature 401, 874-875 (1999).
4. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
5. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193-13197 (1997).
6. Persaud, D., Zhou, Y., Siliciano, J. M. & Siliciano, R. F. Latency in human immunodeficiency virus type1infection:noeasy answers. J. Virol. 77, 1659-1665 (2003).
7. Ho, Y. C. et al. Replication-competent noninduced proviruses inthe latent reservoir increase barrier to HIV-1 cure. Cell 155, 540-551 (2013).
8. Liu, J. et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants inrhesus monkeys. J. Virol. 84, 10406-10412 (2010).
9. Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
10. Liu, J. et al. Immune controlof an SIV challenge by a T-cell-based vaccine inrhesus monkeys. Nature 457, 87-91 (2009).
11. Cline, A. N., Bess, J. W., Piatak, M., Jr & Lifson, J. D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303-312 (2005).
12. Nowak, M. A. et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 71, 7518-7525 (1997).
13. Palmer, S. et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41, 4531-4536 (2003).
14. Whitney, J. B. et al. T-cell vaccination reduces simian immunodeficiency virus levels in semen. J. Virol. 83, 10840-10843 (2009).
15. Rosenbloom, D. I., Hill, A. L., Rabi, S. A., Siliciano, R. F. & Nowak, M. A. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature Med. 18, 1378-1385 (2012).
16. 1cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl Acad. Sci. USA 109, 9523-9528 (2012).
17. Haase, A. T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223 (2010).
18. Ananworanich, J. et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 7, e33948 (2012).
19. von Wyl, V. et al. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE 6, e27463 (2011).
20. Hocqueloux, L. et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J. Antimicrob. Chemother. 68, 1169-1178 (2013).
21. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
22. Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22, 1583-1588 (2008).
23. mne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72, 4265-4273 (1998).
24. Tsai, C. C. et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270, 1197-1199 (1995).
25. Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).
26. Stöhr, W. et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapyinprimary infection correlates with timeontherapy. PLoS ONE8, e78287 (2013).
27. Rosenberg, E. S. et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS ONE 5, e10555 (2010).
28. Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835 (2013).
29. Liu, J., Li, H., Iampietro, M. J. & Barouch, D. H. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J. Virol. 86, 7829-7835 (2012).